Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade
Ilaria Penna(Fondazione IRCCS Istituto Nazionale dei Tumori), Andrea Anichini(Fondazione IRCCS Istituto Nazionale dei Tumori), Federica Perrone(University of Bari Aldo Moro), Loredana Cleris(Fondazione IRCCS Istituto Nazionale dei Tumori), Giulia Grazia(University of Milan), Roberta Mortarini(Scripps Research Institute), Gabriella Nicolini(University of Milano-Bicocca), Benedetta Picciani(Fondazione IRCCS Istituto Nazionale dei Tumori), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Alessandra Molla(Fondazione IRCCS Istituto Nazionale dei Tumori), Filippo de Braud(University of Milan)
Cited by 30
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835